Librexia-Stroke
Posted Date: Feb 19, 2025
- Investigator: Matthew Flaherty
- Specialties: Neurology, Stroke
- Type of Study: Drug
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack. The primary hypothesis of this study is that milvexian 25 mg twice daily in addition to standard-of-care is superior to placebo in addition to standard-of-care in reducing the risk of the primary endpoint of ischemic stroke in participants with an acute ischemic stroke or high-risk TIA.
Criteria:
Patients From Ucmc That Are >40 Years Old, Ischemic Stroke With A Nihss 7 Or Greater, Confirmed On Neuroimaging, Or Undergoing Thromectomy, Or High Risk Tia With Abcd^2 Score Of 6 Or Greater. Patients Must Be Able To Be Randomized Within 48 Hours Of Last Known Normal.
Keywords:
Stroke, Ischemic, Tia
For More Information:
Marchele Nowell-Bostic
NULL
nowellme@ucmail.uc.edu